期刊
NANOMEDICINE
卷 10, 期 3, 页码 375-386出版社
FUTURE MEDICINE LTD
DOI: 10.2217/nnm.14.122
关键词
cancer imaging; iron oxide magnetic nanoparticles (MNPs); MRI; prostate cancer; prostate specific membrane antigen (PSMA); targeted imaging; targeted nanoparticles
资金
- Cancer Australia
- Prostate Cancer Foundation of Australia [NHMRC-510239, PG-0409]
Aim: To evaluate the potential of newly-developed, biocompatible iron oxide magnetic nanoparticles (MNPs) conjugated with J591, an antibody to an extracellular epitope of PSMA, to enhance MRI of prostate cancer. Materials & methods: Specific binding to PSMA by J591-MNP was investigated in vitro. MRI studies were performed on orthotopic tumor-bearing NOD.SCID mice 2 h and 24 h after intravenous injection of J591-MNPs, or non-targeting MNPs. Results & conclusion: In vitro, MNPs did not affect prostate cancer cell viability, and conjugation to J591 did not compromise antibody specificity and enhanced cellular iron uptake. Magnetic resonance contrast of tumors was increased in vivo using PSMA-targeting MNPs, but not by non-targeting MNPs. This provides proof-of-concept that PSMA-targeting MNPs have potential to enhance magnetic resonance detection/localization of prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据